報價延遲最少15分鐘:2025/05/28 20:51 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
24.4257 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.36/--
|
|
企業價值
3.14B
|
| 資產負債 |
|
每股賬面淨值
0.42
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
221.98M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/28 20:51 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China. |